JP2009537478A - レパグリニドとメトホルミンを含む錠剤配合物 - Google Patents

レパグリニドとメトホルミンを含む錠剤配合物 Download PDF

Info

Publication number
JP2009537478A
JP2009537478A JP2009510416A JP2009510416A JP2009537478A JP 2009537478 A JP2009537478 A JP 2009537478A JP 2009510416 A JP2009510416 A JP 2009510416A JP 2009510416 A JP2009510416 A JP 2009510416A JP 2009537478 A JP2009537478 A JP 2009537478A
Authority
JP
Japan
Prior art keywords
weight
tablet
repaglinide
metformin
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009510416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537478A5 (https=
Inventor
耕一 和田
晃 藤田
学 中谷
トーマス フリートル
Original Assignee
ノヴォ ノルディスク アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォ ノルディスク アクティーゼルスカブ filed Critical ノヴォ ノルディスク アクティーゼルスカブ
Publication of JP2009537478A publication Critical patent/JP2009537478A/ja
Publication of JP2009537478A5 publication Critical patent/JP2009537478A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009510416A 2006-05-13 2007-05-10 レパグリニドとメトホルミンを含む錠剤配合物 Ceased JP2009537478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06009902 2006-05-13
EP06121953 2006-10-09
PCT/EP2007/054510 WO2007131930A1 (en) 2006-05-13 2007-05-10 Tablet formulation comprising repaglinide and metformin

Publications (2)

Publication Number Publication Date
JP2009537478A true JP2009537478A (ja) 2009-10-29
JP2009537478A5 JP2009537478A5 (https=) 2010-07-01

Family

ID=38293358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510416A Ceased JP2009537478A (ja) 2006-05-13 2007-05-10 レパグリニドとメトホルミンを含む錠剤配合物

Country Status (4)

Country Link
US (2) US20090252790A1 (https=)
EP (1) EP2026787B1 (https=)
JP (1) JP2009537478A (https=)
WO (1) WO2007131930A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510875A (ja) * 2009-11-13 2013-03-28 ブリストル−マイヤーズ スクイブ カンパニー 速放性錠剤製剤
JP2016535791A (ja) * 2013-11-12 2016-11-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
JP2018199674A (ja) * 2017-05-29 2018-12-20 第一三共株式会社 認知症治療薬を含有する口腔内崩壊性錠剤
US12065432B2 (en) 2007-12-07 2024-08-20 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US12508231B2 (en) 2012-01-25 2025-12-30 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2073796A1 (en) * 2006-09-29 2009-07-01 Novo Nordisk A/S Pharmaceutical formulation comprising metformin and repaglinide
FI20080355A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi metforminia käsittävien tablettien valmistamiseksi
CN101756971B (zh) * 2008-10-09 2013-09-18 北京德众万全药物技术开发有限公司 一种盐酸二甲双胍瑞格列奈的口服固体药物组合物
RU2482846C2 (ru) * 2011-04-12 2013-05-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция и способ получения противодиабетической композиции
CN102319245B (zh) * 2011-07-08 2014-07-09 杭州华东医药集团新药研究院有限公司 一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备
CN102283813B (zh) * 2011-07-28 2017-05-24 万全万特制药江苏有限公司 一种含有瑞格列奈的药物组合物及其制备方法
WO2013074049A1 (en) * 2011-11-03 2013-05-23 Mahmut Bilgic Micronized metformin
WO2013077825A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
CN103494816B (zh) * 2013-09-29 2019-06-14 威海迪素制药有限公司 一种治疗糖尿病的药物组合物
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN105535980B (zh) * 2015-12-24 2019-02-26 江苏豪森药业集团有限公司 稳定的瑞格列奈药物组合物及其制备方法
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
CN114007591A (zh) * 2019-06-17 2022-02-01 帝斯曼知识产权资产管理有限公司 包含经喷雾干燥的维生素b12的固体药物剂型
CN114555811B (zh) 2019-10-16 2025-03-25 拜耳公司 用于改善阿卡波糖形成的方法
LT6874B (lt) 2020-04-17 2021-12-10 Lietuvos sveikatos mokslų universitetas Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
CN117547533A (zh) * 2022-09-16 2024-02-13 广州新济药业科技有限公司 瑞格列奈包覆物、瑞格列奈片及其制备方法
LT7129B (lt) 2023-08-22 2025-03-25 Lietuvos sveikatos mokslų universitetas Natrio dichloroacetato ir valpro rūgšties druskų derinys, skirtas virusinėms ir bakterinėms infekcijoms, ir uždegiminėms ligoms gydyti

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU7906898A (en) * 1997-06-13 1998-12-30 Novo Nordisk A/S Novel niddm regimen
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
ATE508738T1 (de) * 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2007056387A2 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012050090; 佐川良寿: 医薬品製剤技術 , 2002, ｐｐ．６２-６３, 株式会社シーエムシー出版 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12065432B2 (en) 2007-12-07 2024-08-20 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP2013510875A (ja) * 2009-11-13 2013-03-28 ブリストル−マイヤーズ スクイブ カンパニー 速放性錠剤製剤
JP2015129142A (ja) * 2009-11-13 2015-07-16 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 速放性錠剤製剤
US12508231B2 (en) 2012-01-25 2025-12-30 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP2016535791A (ja) * 2013-11-12 2016-11-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
JP2018199674A (ja) * 2017-05-29 2018-12-20 第一三共株式会社 認知症治療薬を含有する口腔内崩壊性錠剤
JP7023186B2 (ja) 2017-05-29 2022-02-21 第一三共株式会社 認知症治療薬を含有する口腔内崩壊性錠剤

Also Published As

Publication number Publication date
EP2026787B1 (en) 2013-12-25
WO2007131930A1 (en) 2007-11-22
US20090252790A1 (en) 2009-10-08
US20120012499A1 (en) 2012-01-19
EP2026787A1 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
EP2026787B1 (en) Tablet formulation comprising repaglinide and metformin
JP5158919B2 (ja) 延長放出経口用量組成物
ES2452019T3 (es) Comprimido bicapa que comprende telmisartán y amlodipino
US20050267125A1 (en) High drug load tablet
EP2448561B1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
AU2010260373A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
EP4112047B1 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
US20130059002A1 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
CA2942877A1 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
TWI889851B (zh) 阿卡拉布替尼馬來酸鹽劑型
US20160199396A1 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EP1100472B1 (en) Pharmaceutical compositions comprising ibuprofen and domperidone
CA2918707A1 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
JP2024524113A (ja) シタグリプチン、ダパグリフロジン及びメトホルミンを含む経口用複合錠剤
EP2839829B1 (en) Sustained release tablet containing levodropropizine and method for preparing same
US8263124B2 (en) Anthistamine-decongestant pharmaceutical compositions
CN101208085B (zh) 1-[(3-羟基-金刚烷基-1-基氨基)-乙酰基]-吡咯烷基-2(s)-腈的调释制剂
TWI734046B (zh) 包含替米沙坦或其藥學上可接受鹽類之具有改良的吸濕性質和溶解速率之製劑
WO2025140767A1 (en) Stable pharmaceutical composition containing dapagliflozin and sitagliptin and process for the preparation thereof
EP4633613A1 (en) Pharmaceutical composition comprising rupatadine and montelukast
HK1169309B (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
AU2010200509A1 (en) High drug load tablet

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150630

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20151221